UCB is a global biopharmaceutical company focused on the discovery and development of innovative medicines and solutions to transform the lives of people living with severe diseases of the immune system or of the central nervous system. The Company is continuously working to advance science and embrace new knowledge. Patients inspire UCB to deliver value through cutting-edge science, innovative drugs, and practical solutions – so that they and their caregivers can get on with their lives. The Company has approximately 8,400 people in nearly 40 countries. UCB is listed on Euronext Brussels. Find out more at www.ucb.com and follow the Company on Twitter: @UCB_news
Role within HIPPOCRATES
Within the HIPPOCRATES project, UCB is the EFPIA co-lead. UCB is contributing expertise in bioinformatics, data management, biomarker discovery and clinical development across all work packages and is co-leading work packages 2 and 5.